These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 27239871)

  • 1. Digital Direct-to-Consumer Advertising: A Perfect Storm of Rapid Evolution and Stagnant Regulation Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters".
    Mackey TK
    Int J Health Policy Manag; 2016 Feb; 5(4):271-4. PubMed ID: 27239871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters.
    Kim H
    Int J Health Policy Manag; 2015 Aug; 4(12):813-21. PubMed ID: 26673465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Considering the Future of Pharmaceutical Promotions in Social Media Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters".
    Carpentier FR
    Int J Health Policy Manag; 2016 Feb; 5(4):283-5. PubMed ID: 27239874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Tip of the Iceberg of Misleading Online Advertising Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters".
    Mintzes B
    Int J Health Policy Manag; 2016 Feb; 5(5):329-31. PubMed ID: 27239883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: Teaching Drug Marketers How to Inform Better or Spin Better? Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters".
    Doran E
    Int J Health Policy Manag; 2016 Feb; 5(5):333-5. PubMed ID: 27239884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The rise of digital direct-to-consumer advertising?: Comparison of direct-to-consumer advertising expenditure trends from publicly available data sources and global policy implications.
    Mackey TK; Cuomo RE; Liang BA
    BMC Health Serv Res; 2015 Jun; 15():236. PubMed ID: 26084705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Still the Great Debate - "Fair Balance" in Direct-to-Consumer Prescription Drug Advertising Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters".
    Rollins BL
    Int J Health Policy Manag; 2016 Feb; 5(4):287-8. PubMed ID: 27239875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Conundrum of Online Prescription Drug Promotion Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters".
    Wanasika I
    Int J Health Policy Manag; 2016 Mar; 5(6):391-2. PubMed ID: 27285519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and Global Health implications of social media in direct-to-consumer drug advertising.
    Liang BA; Mackey TK
    J Med Internet Res; 2011 Aug; 13(3):e64. PubMed ID: 21880574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmaceutical companies and their drugs on social media: a content analysis of drug information on popular social media sites.
    Tyrawski J; DeAndrea DC
    J Med Internet Res; 2015 Jun; 17(6):e130. PubMed ID: 26032738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Future Challenges and Opportunities in Online Prescription Drug Promotion Research Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters".
    Southwell BG; Rupert DJ
    Int J Health Policy Manag; 2016 Jan; 5(3):211-3. PubMed ID: 26927597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical Marketing in the United States, 1997-2016.
    Schwartz LM; Woloshin S
    JAMA; 2019 Jan; 321(1):80-96. PubMed ID: 30620375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promotion of prescription drugs to consumers.
    Rosenthal MB; Berndt ER; Donohue JM; Frank RG; Epstein AM
    N Engl J Med; 2002 Feb; 346(7):498-505. PubMed ID: 11844852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fair Balance and Adequate Provision in Direct-to-Consumer Prescription Drug Online Banner Advertisements: A Content Analysis.
    Adams C
    J Med Internet Res; 2016 Feb; 18(2):e33. PubMed ID: 26892749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The federal regulation of prescription drug advertising and promotion.
    Kessler DA; Pines WL
    JAMA; 1990 Nov; 264(18):2409-15. PubMed ID: 2231998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct-to-consumer advertising affects provider / patient relationship.
    Contracept Technol Update; 1998 Dec; 19(12):153-5. PubMed ID: 12321805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct-to-physician and direct-to-consumer advertising: Time to have stringent regulations.
    Kannan S; Gowri S; Tyagi V; Kohli S; Jain R; Kapil P; Bhardwaj A
    Int J Risk Saf Med; 2015; 27(2):77-83. PubMed ID: 26410010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Critical Test of the Beneficial Consequences of Lifting the Ban on Direct-to-Consumer Advertising for Prescription Drugs in Italy: Experimental Exposure and Questionnaire Study.
    Schulz PJ; Crosignani F; Petrocchi S
    J Med Internet Res; 2023 Jul; 25():e40616. PubMed ID: 37459159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A decade of direct-to-consumer advertising of prescription drugs.
    Donohue JM; Cevasco M; Rosenthal MB
    N Engl J Med; 2007 Aug; 357(7):673-81. PubMed ID: 17699817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug Advertising Violations: A Longitudinal Trend Analysis of FDA Enforcement Letters from 2005 to 2019.
    Zagrodney KAP; Sheikhan NY; Pinto A; Sheikhan T; Witek TJ
    Pharmaceut Med; 2021 Jan; 35(1):31-38. PubMed ID: 33453042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.